Lai et al. demonstrated that miR-338 inhibited HCC progression and glycolysis by targeting LRP6, and exosomal circFBLIM1 acted as a sponge for miR-338 to promote HCC progression [142]. This evidence concerns the gene LRP6 and hepatocellular carcinoma.